I'm saying that when you make your recommendations, you always consider the effectiveness in terms of what it provides in addition. But when you do your analysis, you also take the cost into account.
Consequently, there is a tremendous gap if 62% of the products are approved in Quebec for reimbursement whereas British Columbia approves only 15%. That means that Quebec is reimbursing too much money for drugs, especially since you are saying that there may be other medications that are just as effective but less costly.